At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 96 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
CLIMB is a study for people with primary central nervous system (CNS) lymphoma, a cancer that affects the brain or spinal cord. The study looks at scans (imaging) and molecular markers (biomarkers) to learn more about this illness. The study is run by the Royal Marsden NHS Foundation Trust.
Who can take part
- You are aged 18 or over.
- You have been diagnosed with primary CNS lymphoma, based on either a scan or a tissue sample (biopsy).
- You have not had any treatment aimed at the CNS before. Taking steroids beforehand is allowed.
- You are able to give your own agreement (consent) to take part. If the illness affects your ability to decide, a representative can agree on your behalf, following English or Scottish law.
Who may not be able to
- The lymphoma is also present outside the CNS (the brain and spinal cord).
What taking part involves
- • The study involves scans (imaging) and tests looking at molecular markers (biomarkers).
- • Any other tests or treatments involved are not stated — ask the trial team.
Time commitment: Visits, duration, and what taking part involves are not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 36
- Started
- 2023-09-18
- Last checked
- 2024-11
Plain English Summary
What is this study?
- • Testing a new treatment for cns lymphoma
- • Clinical study - 36 participants
- • A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with cns lymphoma
Where?
- • Sutton - The Royal Marsden NHS Foundation Trust, Downs Road
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
More detail
As a single centre exploratory study, this trial will recruit patients with newly diagnosed primary CNS lymphoma and will look at the molecular aspects of the disease in the tissue collection and imaging response assessments using CCA with respect to progression free survival.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓A radiological or histological diagnosis of primary CNS lymphoma.
- ✓Have not received prior CNS directed therapy. Prior use of steroids is permitted.
- ✓Participants aged ≥18 years old.
Who cannot take part
- ✗\- Involvement of lymphoma outside of the CNS
See the full criteria
Where Is This Study? (1 UK site)
The Royal Marsden NHS Foundation Trust, Downs Road
Sutton SM2 5PT, United Kingdom
How to Get in Touch
GI and Lymphoma Unit
Sponsor contactCONTACT